Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe
How this was made
The 30-second read
Why it matters
The excerpt quantifies revenues and losses for the six months ended June 30, 2026 and notes no dividend; it does not provide new clinical endpoints, regulatory actions, or commercialization updates beyond forward-looking references.
Market read
Traders get updated financial condition figures for the quarter and six-month period, but the excerpt lacks a fresh operational or regulatory catalyst.
What to watch
Related-party payment disclosure ($583k in Q2) and the waiver-based supplementary reporting could matter for governance scrutiny, but the excerpt does not indicate any change in risk beyond routine disclosure.
Six-month revenues from ordinary activities were 1,503 US$’000, up 28 %, while loss for the period attributable to members was (52,118 ) US$’000, up 22 % from the prior-year loss.
Revenue increased 28 %, but losses from ordinary activities after tax and loss for the period attributable to members both increased versus the prior-year period.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenues from ordinary activitiesGAAP | $1.50M | – | 28 % |
| Loss from ordinary activities after taxGAAP | −$51.67M | – | 20 % |
| Loss for the period attributable to membersGAAP | −$52.12M | – | 22 % |
| Aggregate amount of payments to related parties and their associatesother | $583K | – | – |
Capital returns
- No dividend has been proposed or declared for the reporting period.
What drove it
- Revenues from ordinary activities increased by 329 US$’000, or 28 %, for the six months to June 30, 2026.
- The filing identifies DurAVR® Transcatheter Heart Valve as Anteris’ lead product and describes it as designed to treat aortic stenosis.
Concerns
- Loss from ordinary activities after tax increased by (8,682 ) US$’000, or 20 %, versus the prior-year six-month period.
- Loss for the period attributable to members increased by (9,420 ) US$’000, or 22 %, versus the prior-year six-month period.
- No quarterly revenue, quarterly loss, margin, operating expense, liquidity, or cash-burn figures were provided in the supplied filing text.
What to watch
- Revenue conversion beyond the reported six-month revenues from ordinary activities of 1,503 US$’000.
- The loss trajectory following the reported loss for the period attributable to members of (52,118 ) US$’000.
- Developments regarding the PARADIGM Trial, CMS reimbursement eligibility, clinical development timelines and potential commercialization, which the filing identifies as forward-looking matters.
Balance sheet and cash flow
- During the second quarter of 2026, the aggregate amount of payments to related parties and their associates was US$583 thousand.
- These payments were included in cash flows from operating activities.
- There were no payments to related parties or their associates included in cash flows from investing activities.
Analysis
The supplied filing reports six-month results for the period ended June 30, 2026. Revenues from ordinary activities were 1,503 US$’000, compared with 1,174 US$’000 in 2025, an increase of 329 US$’000 or 28 %. The filing does not provide a revenue breakdown by segment, product, geography, or quarter, so the source of the increase is not disclosed.
Profitability remained the central weakness in the reported results. Loss from ordinary activities after tax was (51,675 ) US$’000, compared with (42,993 ) US$’000 in the prior-year six-month period, a 20 % increase in the loss. Loss for the period attributable to members was (52,118 ) US$’000 versus (42,698 ) US$’000, a 22 % increase in the loss.
The release provides limited cash-flow and capital-allocation disclosure. It states that US$583 thousand of payments to related parties and their associates occurred during the second quarter of 2026 and were included in operating cash flows. No dividend was proposed or declared for the reporting period. Cash, debt, operating cash flow, free cash flow, repurchases, and broader capital resources were not reported in the supplied text.
The filing identifies DurAVR® THV as the company’s lead product and refers to the PARADIGM Trial, CMS reimbursement eligibility, clinical development timelines and potential commercialization as forward-looking subjects. It provides no quantified outlook or financial guidance. With revenue growth reported only for the six-month period and losses increasing versus the prior-year period, the next disclosures should clarify the quarterly revenue cadence, spending profile, liquidity, and progress on the identified clinical and commercialization items.
Not in the filing
stated, not guessed- Quarterly revenue for the quarter ended June 30, 2026.
- Quarterly prior-year and prior-quarter revenue comparisons.
- Revenue by segment, product, geography, or customer category.
- Gross profit and gross margin.
- Operating expenses.
- Operating income or loss.
- Net income or loss under a separately labeled net-income line.
- GAAP earnings or loss per share.
- Non-GAAP revenue, gross margin, operating income, net income, or earnings per share.
- Cash and cash equivalents.
- Debt.
- Operating cash flow.
- Free cash flow.
- Capital expenditures.
- Share repurchases.
- Dividend amount per share.
- Forward financial guidance for revenue, gross margin, operating expenses, tax rate, or other metrics.
- Prior-quarter outlook for comparison with actual results.
- Named executive commentary or attributable executive quotes.
- Explanation of the drivers of the revenue increase or loss increase.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8-K (Item 2.02) attaches results for announcement to the market and states the company’s 10-Q for the quarter ended June 30, 2026 was filed.
Ticker impact
Anteris filed an 8-K with 10-Q results showing six-month revenues of $1.503M and a $51.675M loss from ordinary activities after tax.
Near-term bias likely negative or neutral, as the disclosed losses remain large and the excerpt does not add a new catalyst.
The only concrete numbers provided are revenue and losses for the six months ended June 30, 2026, plus related-party payments; the clinical and reimbursement items are referenced as forward-looking without new data.
Market effects
Limited read-through for structural heart device peers because the excerpt does not include new trial outcomes or reimbursement decisions.
Mostly company-specific; no cross-market policy or procurement signal is provided.
Low, as the disclosure is a routine SEC/ASX financial update without new global regulatory or commercial developments.
Counterpoint
If the full 10-Q or the referenced ASX announcement contains trial or reimbursement updates, the excerpt may understate the true catalyst; traders should verify the linked materials.
Key entities
- issuerAnteris Technologies Global Corp.
NASDAQ-listed medical device company filing an 8-K with 10-Q results for the quarter ended June 30, 2026.
- productDurAVR Transcatheter Heart Valve
Lead product referenced in the company description; no new performance or trial data is provided in the excerpt.
- clinical_programPARADIGM Trial
Referenced in forward-looking statements, but no new trial results are disclosed in the excerpt.
